TrialDiabetes & metabolism2017

Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

B Cariou et al.PubMed ↗Publisher ↗

No numbers read from the abstract.